Physician profile
Charles K Simpson
NPI 1871527754
$1,065.83
in general payments reported to CMS, 2019-2025
16 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $458 · 2022: $205 · 2023: $112 · 2024: $71.89 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $362.18 | 2021-2023 | Pylarify |
| Siemens Medical Solutions USA, INC. | $174.33 | 2025 | |
| Dendreon Pharmaceuticals LLC | $115.72 | 2021-2022 | |
| Amgen INC. | $85.00 | 2021 | |
| Myriad Genetic Laboratories, INC. | $51.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $41.64 | 2024-2025 | |
| Myovant Sciences INC. | $41.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.04 | 2021 | |
| Jazz Pharmaceuticals INC. | $33.17 | 2024-2025 | |
| Daiichi Sankyo INC. | $22.72 | 2024 | Enhertu |
| Janssen Biotech, INC. | $21.35 | 2021 | |
| Astellas Pharma US INC | $19.60 | 2022 | |
| Eisai INC. | $18.70 | 2024 | |
| Pfizer INC. | $17.03 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $13.72 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.